

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

### VOLUNTARY ANNOUNCEMENT

#### RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2023

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that abstracts and posters of six different research updates on KN046 and KN026 will be presented at the 2023 congress of European Society for Medical Oncology (“**ESMO Congress 2023**”), an influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO Congress 2023 will take place from October 20, 2023 to October 24, 2023, local time, in Madrid, Spain, whereby the latest cutting-edge data from all around the world will be disseminated. Such research updates on KN046 and KN026 will also be presented at the Company’s website at <http://www.alphamabonc.com> correspondingly. Details are set out below:

Title	Abstract No.	Poster No.
<b>KN046 (PD-L1/CTLA-4 bispecific antibody)</b>		
• Preliminary efficacy and safety of KN046 in patients with metastatic NSCLC who previously treated with immune checkpoint inhibitor(s)	2155	1459P
• Updated results of the efficacy and safety of KN046 in patients with metastatic NSCLC who failed prior EGFR-TKI(s)	2230	1330P
• The preliminary data from a single-arm, open-label, multi-center, phase II clinical trial: KN046 combined with axitinib as first-line treatment for NSCLC	3226	1449P
• KN046 in patients with thymic carcinoma: a prospective, single-arm, multi-center, phase II study	5843	2186P

Title	Abstract No.	Poster No.
<b>KN026 (HER2/HER2 bispecific antibody)</b>		
<ul style="list-style-type: none"> <li>Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic BC</li> </ul>	3575	418P
<ul style="list-style-type: none"> <li>KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced BC: a single-arm, multi-center, phase II study</li> </ul>	1300	247P

## ABOUT KN046

KN046 is a global innovative PD-L1/CTLA-4 bispecific antibody independently developed by the Group, targeting both PD-L1 and CTLA-4 with a clear structural differentiation to improve localization with the tumor microenvironment and to reduce off-target toxicity. Approximately 20 clinical trials of KN046 in different stages covering more than 10 types of tumors including NSCLC, triple-negative BC, esophageal squamous cell carcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma and thymic carcinoma have been conducted in China, the United States of America and Australia. The results of these clinical trials have demonstrated a preliminary profile of good safety and promising efficacy of KN046. Among them, the preliminary results of phase II clinical trials in China indicate promising activity of KN046 for NSCLC, pancreatic ductal adenocarcinoma, hepatocellular carcinoma and triple-negative BC as a single therapy and in combination therapy with chemotherapy. The Group has published preliminary promising safety and efficacy data of KN046 in patients who have failed prior treatments with immune checkpoint inhibitors. The Group is conducting pivotal clinical trials in NSCLC and pancreatic ductal adenocarcinoma. The Group is also exploring cooperation opportunities to conduct clinical trials of KN046 in combination with its business partners' drug candidates, to achieve better therapeutic effects.

The preclinical and clinical trial results of KN046 have shown promising efficacy and indicated that KN046 is able to significantly reduce toxicity to human peripheral system. The Company believes that KN046 has the potential to become a breakthrough in cancer immunotherapy.

## ABOUT KN026

KN026 was designed to be a global-level next-generation HER2-targeted therapy. With its innovative structure, it binds simultaneously to 2 distinct clinically validated epitopes of HER2 (paratope II and IV), and maintains a wild type Fc region. This results in (i) a dual blockade of HER2-related signaling pathways, (ii) strengthened binding to HER2 receptors, (iii) a reduction of HER2 proteins on the cell surface, and (iv) increased tumor killing effect through intact antibody dependent cell-mediated cytotoxicity. These binding mechanisms enable KN026 to have excellent tumor suppressive effect. Several phase I/II clinical trials of KN026 have shown good preliminary efficacy in patients with advanced HER2-positive BC and GC/GEJ. Currently, two phase III clinical trials of KN026 as second-line or above treatment of HER2-positive GC/GEJ and as first-line treatment of HER2-positive BC are ongoing in China.

## ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house clinical pipeline of the Company includes the oncology drug candidates with one approved for marketing by the National Medical Products Administration of China (國家藥品監督管理局), three in late clinical stage and two in phase I clinical trial stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological new drug candidates that could potentially benefit patients globally.

## DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

“axitinib”	a targeted cancer drug used to treat kidney cancer after previous treatment has not been effective
“BC”	breast cancer
“CTLA-4”	cytotoxic T-lymphocyte-associated protein 4
“docetaxel”	a medication used to treat cancer (such as breast, lung, prostate, stomach, and head/neck cancer)
“EGFR-TKI(s)”	epidermal growth factor receptor tyrosine kinase inhibitor(s), used in the first-line treatment of NSCLC
“GC”	gastric cancer
“GEJ”	gastroesophageal junction cancer
“HER2”	human epidermal growth factor receptor 2
“HER2-positive”	HER2 with immunohistochemistry test score of 3+ or HER2 gene amplification
“NSCLC”	non-small cell lung cancer
“PD-L1”	programmed death ligand 1, a protein on the surface of a normal cell or a cancer cell that can attach to programmed cell death protein 1 on the surface of the T-cell that causes the T-cell to turn off its ability to kill the cancer cell

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop, or ultimately market, KN046 and KN026, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, August 10, 2023

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.*